Citius Oncology, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|
| Revenue | $1.5M | $1.7M | $3.9M |
| Cost of Revenue | $491.8K | $328.9K | $789.2K |
| Gross Profit | $1.0M | $1.3M | $3.2M |
| Gross Margin | 67.1% | 80.3% | 80.0% |
| Operating Expenses | |||
| Research & Development | $218.5K | $1.1M | $1.0M |
| SG&A Expense | $4.2M | $23.6M | $2.9M |
| Operating Income | $-8.7M | $-28.6M | $-5.3M |
| Operating Margin | -583.5% | -1,716.2% | -133.2% |
| Interest Expense | $198.3K | — | — |
| Pretax Income | $-9.0M | $-26.8M | $-5.3M |
| Income Tax Expense | $-107.3K | $-231.2K | $264.2K |
| Net Income | $-8.9M | $-26.6M | $-5.5M |
| Net Margin | -597.4% | -1,596.0% | -140.3% |
| EPS (Basic) | $-0.08 | $-0.27 | $-0.06 |
| EPS (Diluted) | $-0.08 | $-0.27 | $-0.06 |
| Shares Outstanding (Basic) | 107.9M | 100.0M | 87.5M |
| Shares Outstanding (Diluted) | 107.9M | 100.0M | 87.5M |
| Dividends Per Share | — | — | — |